Equity Profile

RGEN

REPLIGEN CORP

Health CareLife Sciences Tools & Services$6.9B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its business and capture market share, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RGEN Q2-2026 Earnings Preview

Context

Company Snapshot

Repligen Corp (RGEN) operates in the health care sector, specifically within life sciences tools and services. The company focuses on providing innovative solutions for bioprocessing, which is crucial for the production of biologic drugs. As the demand for biologics continues to grow, Repligen's role in supporting this industry makes it an important player in health care.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In Q1-2026, Repligen reported an EPS of $0.48, exceeding expectations by 25%. The stock reacted positively, increasing by 6.26% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as there are no analyst estimates available for this quarter. Investors will be keen to see if Repligen can continue its trend of beating EPS estimates.

Bull Case

If Repligen can deliver strong EPS and revenue growth, it may reinforce investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative reaction in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's strong track record of beating EPS estimates, this figure will be crucial for determining market sentiment.

How has revenue growth trended in the last quarter?

Investors will be looking for insights into revenue performance to gauge the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Repligen's potential for strong revenue growth driven by increasing demand for bioprocessing solutions.

Supporting Evidence

Repligen has consistently beaten EPS estimates, indicating stronger-than-expected performance.

The options market is pricing a smaller move than historical averages, suggesting complacency among investors.

Insider selling could indicate a lack of confidence in short-term performance, which may not reflect the company's long-term potential.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Repligen can maintain its growth momentum and profitability in a competitive landscape.

Bull Confirmed If

An EPS of $0.50 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $0.40 would confirm the bear case, suggesting potential issues with growth.

Pre-Earnings Positioning

Options Market

Implied Move

±4.1%

Historical Avg

±6.4%

Pricing cheap

The options market is pricing in a move of about 4.1% in either direction following the earnings report, indicating some uncertainty among investors.

Options are pricing ±4.1% while RGEN has averaged ±6.4% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.6%

30d HV

59.6%

Calls (72K)P/C Ratio: 38.48Puts (1K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$536,480.00

3,832 sh

1 insider

Net

$536,480.00

Net selling

Most Active Insiders· 1 open-market trade

Chief Executive OfficerLoeillot Olivier
$536,480.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations, history suggests a potential stock increase of around 3.95%, confirming the company's growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss on EPS could lead to a decline in stock price, with historical data suggesting an average drop of around 4.72%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in bioprocessing technology.
2Insights into customer demand trends and how they are impacting revenue.
3Management's outlook on the competitive landscape and market opportunities.
4Details on cost management and gross margin performance.
5Any commentary on potential challenges or risks facing the business.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its business and capture market share, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RGEN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In Q1-2026, Repligen reported an EPS of $0.48, exceeding expectations by 25%. The stock reacted positively, increasing by 6.26% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as there are no analyst estimates available for this quarter. Investors will be keen to see if Repligen can continue its trend of beating EPS estimates.

Bull Case

If Repligen can deliver strong EPS and revenue growth, it may reinforce investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative reaction in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's strong track record of beating EPS estimates, this figure will be crucial for determining market sentiment.

How has revenue growth trended in the last quarter?

Investors will be looking for insights into revenue performance to gauge the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Repligen's potential for strong revenue growth driven by increasing demand for bioprocessing solutions.

Supporting Evidence

Repligen has consistently beaten EPS estimates, indicating stronger-than-expected performance.

The options market is pricing a smaller move than historical averages, suggesting complacency among investors.

Insider selling could indicate a lack of confidence in short-term performance, which may not reflect the company's long-term potential.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Repligen can maintain its growth momentum and profitability in a competitive landscape.

Bull Confirmed If

An EPS of $0.50 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $0.40 would confirm the bear case, suggesting potential issues with growth.

Pre-Earnings Positioning

Options Market

Implied Move

±4.1%

Historical Avg

±6.4%

Pricing cheap

The options market is pricing in a move of about 4.1% in either direction following the earnings report, indicating some uncertainty among investors.

Options are pricing ±4.1% while RGEN has averaged ±6.4% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.6%

30d HV

59.6%

Calls (72K)P/C Ratio: 38.48Puts (1K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$536,480.00

3,832 sh

1 insider

Net

$536,480.00

Net selling

Most Active Insiders· 1 open-market trade

Chief Executive OfficerLoeillot Olivier
$536,480.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations, history suggests a potential stock increase of around 3.95%, confirming the company's growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss on EPS could lead to a decline in stock price, with historical data suggesting an average drop of around 4.72%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in bioprocessing technology.
2Insights into customer demand trends and how they are impacting revenue.
3Management's outlook on the competitive landscape and market opportunities.
4Details on cost management and gross margin performance.
5Any commentary on potential challenges or risks facing the business.